| Revenue growth | 72.6% YoY to ₹43.72 Cr |
|---|---|
| Margins | EBITDA 12.42% vs 16.39% FY26; gross 51.40% vs 54.78% |
| Demand visibility | Marketing push to build B2B and e-commerce demand |
| Management confidence | Delivered as promised; no numeric guidance |
Growth
Revenue +72.6% YoY to ₹43.72 Cr. EBITDA swung to ₹5.43 Cr from −₹0.23 Cr; PAT ₹3.54 Cr from −₹0.78 Cr.
Outlook
Xelix clinics: 100+ in FY27, 500+ in FY28 onward. Debtor days target <130. Xelix FUE HT device test licence applied.
Risks
Gross margin fell to 51.40% from 54.78%, blamed on wars, logistics costs and rupee depreciation. Debtor days rose to 219 from 160.
Investor Presentation filed with NSE, NSE: AAKAAR. Summary written with AI assistance from the document.
Aakaar Medical Technologies Ltd: key numbers
- Share price
- ₹71.00
- Market cap
- ₹100.6 Cr
- Revenue (annual)
- ₹66.96 Cr
- Net profit (annual)
- ₹6.64 Cr
- P/E (TTM)
- 15.2×Sector 52.3×
- Promoter holding
- 67.05%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aakaar Medical Technologies Ltd
All →Aakaar Medical Technologies H1 FY27 Results: Turns Profitable, Net Profit ₹3.5 Cr
Aakaar Medical Technologies Ltd reported revenue from operations of ₹43.7 Cr (+72.7% YoY) and net profit of ₹3.5 Cr for H1 FY27.
- Key figure
- Net profit ₹3.5 Cr
Aakaar Medical Technologies Board Meeting Date
Aakaar Medical Technologies Limited will hold a board meeting on 30-Oct-2026 to consider unaudited half-yearly financial results and ESOP matters.
Aakaar Medical Technologies Other Announcement
Aakaar Medical Technologies Limited submitted its Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2026. The report confirms total issued capital remains at 1,41,72,816 equity shares.
Aakaar Medical Technologies Business Update
Aakaar Medical Technologies provided an operational update for Q1 FY2026-27, detailing expansion in its clinic network, distributor count, and overall sales force effectiveness.
Aakaar Medical Technologies Legal & Regulatory
Aakaar Medical Technologies addressed an NSE notice regarding Regulation 44(3) non-compliance, stating the lapse was inadvertent and that corrective measures have been implemented.
Aakaar Medical Technologies Legal & Regulatory
Aakaar Medical Technologies submitted a share‑capital audit reconciliation reporting issued capital of ₹14.17 Crore. The filing satisfies SEBI (Depositories and Participants) Regulation 76 requirements.
- Value
- ₹14.17 Cr